KDR and non-small cell lung carcinoma: At present, the anti-PD-1 SHR-1210 is being investigated in combination with the vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor, compared with chemotherapy drugs in KRAS-mutant stage IV NSCLC patients (ClinicalTrials.gov identifier: NCT03777124).